Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

383
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
383
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

266
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
266
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

494
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
494
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

353
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
353
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

499
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
499
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

252
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
252

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transcriptomics profiles in intestinal sulfide overproduction, small intestinal bacterial overgrowth, and intestinal methanogen overgrowth.

mSystems·2026
Same author

Reframing sepsis through resistance, disease tolerance and damage: a clinically meaningful conceptual shift?

Intensive care medicine·2026
Same author

Top-down versus step-up approach after endoscopic ultrasound-guided drainage of infected walled-off necrosis: a randomized controlled trial.

Endoscopy·2026
Same author

Methodological concerns in hidradenitis suppurativa genomic and proteomic profiling.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Sepsis associated with Clostridioides difficile infection carries similar mortality to sepsis of other origin: a propensity score-matched analysis.

Scientific reports·2026
Same author

Risk Stratification in Primary Gastric Malignancies in Children, Adolescents, and Young Adults: A SEER-Based Analysis.

Journal of personalized medicine·2026
Same journal

Correction: Peptine et al. Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) and Vancomycin-Resistant Enterococci (VRE) in Nosocomial Infections: A Systematic Review of Resistance, Pathogenesis, and Clinical Management. <i>Microorganisms</i> 2026, <i>14</i>, 428.

Microorganisms·2026
Same journal

Torque Teno Virus (TTV) Plasma Load and Immune Reconstitution in People Living with HIV: A Systematic Review.

Microorganisms·2026
Same journal

Optimizing Bacteriophage Screening and Isolation Methods for Microbial Samples Derived from Different Body Sites of Cattle.

Microorganisms·2026
Same journal

Enhanced Biphenyl Degradation by <i>Rhodococcus</i> sp. TG-1 Under Cr(VI) Stress via Modified Biochar Immobilization.

Microorganisms·2026
Same journal

In Vitro Detection of Biologically Active Staphylococcal Enterotoxins Type B and C1 as an Alternative to In Vivo Testing.

Microorganisms·2026
Same journal

Monitoring Hygiene Protocols and Exploring Alternatives to Counteract Resistant Pathogens: A Case Study from Southern Italy on Healthcare-Associated Infection Control.

Microorganisms·2026
See all related articles

Related Experiment Video

Updated: Aug 8, 2025

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

645

Probiotics in Functional Dyspepsia.

Georgios Tziatzios1, Paraskevas Gkolfakis1, Gabriela Leite2

  • 1Department of Gastroenterology, "Konstantopoulio-Patision" General Hospital, 3-5, Theodorou Konstantopoulou Street, Nea Ionia, 142 33 Athens, Greece.

Microorganisms
|February 25, 2023
PubMed
Summary
This summary is machine-generated.

Probiotics show potential for managing functional dyspepsia (FD) symptoms by influencing gut microbiota. Further research is needed to confirm their efficacy for this complex gastrointestinal disorder.

Keywords:
dyspepsiafunctionalprobioticstreatment

More Related Videos

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

881

Related Experiment Videos

Last Updated: Aug 8, 2025

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes
06:01

Author Spotlight: Reliable and Reproducible In Vitro Assessment of Drug Impact on Rat Intestinal Tubes

Published on: July 26, 2024

645
The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.7K
Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

881

Area of Science:

  • Gastroenterology
  • Microbiology
  • Pharmacology

Background:

  • Functional dyspepsia (FD) is a prevalent, multifactorial gastrointestinal disorder impacting patient quality of life and healthcare systems.
  • The exact causes of FD are not fully understood, with proposed mechanisms including impaired gastric function, brain-gut axis dysfunction, and altered duodenal microbiota.
  • Current treatments for FD lack universal efficacy, necessitating exploration of novel therapeutic strategies.

Purpose of the Study:

  • To review and summarize existing evidence on the effectiveness of probiotics as a treatment for functional dyspepsia.
  • To evaluate the potential of probiotics in alleviating FD symptoms and addressing its underlying pathophysiology.

Main Methods:

  • Systematic review of current scientific literature.
  • Analysis of studies investigating probiotic interventions in patients with functional dyspepsia.
  • Evaluation of reported outcomes related to FD symptom improvement and quality of life.

Main Results:

  • Probiotics have demonstrated potential in alleviating gastrointestinal symptoms in related conditions like Irritable Bowel Syndrome (IBS).
  • Evidence regarding the specific impact of probiotics on the diverse aspects of functional dyspepsia remains inconclusive.
  • Further investigation is required to establish the role of probiotics in FD management.

Conclusions:

  • Probiotics represent a promising, novel therapeutic avenue for functional dyspepsia.
  • The efficacy of probiotics in treating FD requires more robust clinical evidence.
  • Future research should focus on specific probiotic strains and their mechanisms in FD.